Answers are grounded in this paper and cite their sources.
This systematic review analyzes neurological toxicities in plasma cell dyscrasia treated with CAR T-cell therapy, suggesting important implications for patient management.
R.C.—Consulting/Advisory Board: Janssen, Sanofi, Adaptive Biotech, Alexion, Pfizer; Honoraria: Janssen, Sanofi, Adaptive Biotech, Alexion, Pfizer; Research funding: Genentech, AbbVie. The other authors have no financial or other disclosures to declare. Data will be made available after reasonable request by contacting the corresponding author. Figure S1. Figure S2. Figure S3. Table S1. Table S2. Table S3. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
No takes yet. Share an insight, caveat, or question.
Saini et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: